Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2021

Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform

Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform

Published 15 December 2021
Categorized as 2021, 2021, Press release, Invir.IO, Press release, TG4050

Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine

Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine

Published 22 November 2021
Categorized as 2021, Press release, TG4050

Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

20211109 – Transgene BioInvent SITC BT-001 en

Published 9 November 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Transgene reports business update and Q3 2021 financial position

20211104 – Transgene – Q3 Financial update EN

Published 4 November 2021
Categorized as 2021, News-fr-en, Press release

Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021

BT-001 oncolytic virus at SITC 2021

Published 1 October 2021
Categorized as 2021, BT-001, Press release

Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023

Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023

Published 22 September 2021
Categorized as 2021, Press release, News-fr-en, Press release, TG4001, TG4001, TG6002 (FR)

Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

P. Cassier et al. ESMO 2021 Download the poster here Poster Presentation

Published 16 September 2021
Categorized as -others, 2021, Publication, TG6002

Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

Published 16 September 2021
Categorized as 2021, Press release, TG6002

Transgene Announces Upcoming Investor Meetings

Transgene Announces Upcoming Investor Meetings

Published 13 September 2021
Categorized as 2021, News, News-fr-en, Press release

Transgene Participates in New Cancer Research Consortium

Transgene Participates in New Cancer Research Consortium

Published 1 September 2021
Categorized as 2021, Press release, Invir.IO, Press release, TG4001, TG4001

Posts pagination

Page 1 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu